DexCom (DXCM) insider Bridgette Heller files to sell 1,012 shares after grant
Rhea-AI Filing Summary
DexCom, Inc. insider Bridgette P. Heller filed a notice of proposed sale of 1,012 shares of common stock of DXCM, to be sold through Fidelity Brokerage Services LLC on or after August 12, 2026 on NASDAQ. The shares were acquired via restricted stock vesting from the issuer as compensation on September 29, 2021. Heller also reported having sold 1,012 common shares during the past three months on May 12, 2026 for $60,730.12.
Positive
- None.
Negative
- None.
Key Figures
Proposed shares to be sold: 1,012 shares
Aggregate market value of proposed sale: $89,349.48
Prior 3-month sale shares: 1,012 shares
+2 more
5 metrics
Proposed shares to be sold
1,012 shares
Common stock sale through Fidelity on or after August 12, 2026
Aggregate market value of proposed sale
$89,349.48
Value of 1,012 DexCom common shares planned for sale
Prior 3-month sale shares
1,012 shares
Common stock sold on May 12, 2026
Proceeds from prior sale
$60,730.12
Total proceeds from 1,012 shares sold on May 12, 2026
Acquisition date of shares
September 29, 2021
Restricted stock vesting as compensation from issuer
Key Terms
Form 144, Restricted Stock Vesting, Compensation, Securities Sold During The Past 3 Months
4 terms
Form 144 regulatory
"144: Securities To Be Sold"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Restricted Stock Vesting financial
"Common | 09/29/2021 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
Compensation financial
"1012 | 09/29/2021 | Compensation"
Securities Sold During The Past 3 Months regulatory
"144: Securities Sold During The Past 3 Months"
FAQ
What does DexCom (DXCM) Form 144 filed by Bridgette P. Heller disclose?
The Form 144 discloses that Bridgette P. Heller intends to sell 1,012 shares of DexCom common stock through Fidelity on or after August 12, 2026, and that these shares came from restricted stock vesting awarded as compensation.
What DexCom (DXCM) stock sales has Bridgette P. Heller made in the past three months?
The Form 144 notes that Heller sold 1,012 shares of DexCom common stock on May 12, 2026 for total proceeds of $60,730.12. This prior transaction is listed in the section covering securities sold during the past 3 months.
AI-generated analysis. How Rhea-AI works. Not financial advice.